Estrone (E1) Longevity-Medicine Target Ranges: What Your Lab Result Actually Means

What Is Estrone, and Why Does It Matter More After Menopause?

Estrone is one of three biologically active estrogens your body produces, alongside estradiol (E2) and estriol (E3). It is the weakest of the three in terms of receptor binding affinity, yet it becomes the dominant circulating estrogen after your ovaries stop producing significant amounts of estradiol at menopause. Understanding your E1 level is especially relevant if you are postmenopausal, considering hormone therapy, or managing a condition like PCOS or obesity that can drive excess peripheral estrogen conversion.

The Biochemistry in Plain Terms

During your reproductive years, the ovaries produce most of your estradiol. Estrone is a metabolic byproduct of estradiol and, separately, of androstenedione converted in fat cells, the liver, muscle, and skin via the enzyme aromatase. Aromatase activity and its role in estrogen biosynthesis outside the ovaries is well described in the endocrinology literature.

After menopause, ovarian estradiol production falls to near zero. Estrone, made in adipose tissue from adrenal androstenedione, becomes the primary estrogen your body circulates. This is why body composition directly influences your postmenopausal estrogen environment: more adipose tissue means more aromatase activity and higher E1 levels.

The Three Estrogens Are Not Interchangeable

E2 binds the estrogen receptor with roughly 10 times the affinity of E1. Relative receptor binding affinities for estradiol vs. Estrone have been quantified in receptor-binding assays. E1 can act as a weak agonist in its own right and also serves as a reservoir that converts back to E2 in target tissues. This interconversion matters when you interpret lab values: a woman with a high E1 but low E2 may still have meaningful estrogenic activity at the tissue level, though the clinical picture is never that simple.

Estrone Reference Ranges by Life Stage

No single "normal" applies to all women. Estrone fluctuates with the menstrual cycle, rises dramatically in pregnancy, and settles to a new baseline after menopause. Lab reference intervals also differ by assay platform, so comparing values across different laboratories without knowing the assay method can be misleading.

Reproductive Years (Premenopausal)

During the follicular phase of a typical 28-day cycle, serum estrone runs approximately 37 to 138 pg/mL. It peaks around ovulation alongside the estradiol surge, then falls in the luteal phase to roughly 44 to 116 pg/mL before dropping at menstruation. The Endocrine Society's clinical practice guidelines provide reference intervals for reproductive-age women.

These numbers vary considerably between women and between assay methods. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold-standard assay and produces lower, more accurate absolute values than older immunoassay platforms, which are known to overestimate estrogens, particularly at low concentrations. The clinical implications of immunoassay vs. LC-MS/MS for estrogen measurement are reviewed in the Journal of Clinical Endocrinology and Metabolism.

Perimenopause

Perimenopause is defined by menstrual irregularity and spans the years before the final menstrual period, typically beginning in a woman's mid-to-late 40s and lasting two to eight years. Estradiol fluctuates erratically and unpredictably during this window. Estrone also fluctuates but tends to track adipose-derived aromatization more than ovarian output.

A single E1 measurement in perimenopause is rarely diagnostically useful on its own. The FSH level, menstrual pattern, and symptoms together give a clearer picture than any one hormone value. ACOG Practice Bulletin guidance on menopause emphasizes the clinical diagnosis over isolated hormone levels.

Postmenopause

After the final menstrual period (confirmed at 12 months of amenorrhea), typical serum estrone by LC-MS/MS falls in the range of 7 to 40 pg/mL in women not taking hormone therapy. Conventional lab reference intervals often cite a range of approximately 7 to 40 pg/mL for postmenopausal women, but laboratory-specific intervals can differ.

The postmenopausal E1 level is driven primarily by adipose mass, adrenal androgen output, and aromatase activity. Women with higher BMI will generally have higher postmenopausal E1. The relationship between adiposity and postmenopausal estrone has been characterized in the Women's Health Initiative observational cohort.

Longevity-Medicine Target Ranges for Estrone

Longevity-oriented and functional medicine practitioners apply targets that go beyond conventional "not abnormal" reference ranges. The goal is to identify the zone associated with the best long-term outcomes for bone mineral density, cardiovascular health, cognitive function, and tissue integrity, while staying below levels that may raise cancer risk. No randomized trial has prospectively tested a specific E1 target and measured longevity outcomes; this framework is derived from observational cohort data, mechanistic studies, and expert consensus rather than direct trial evidence. That evidence gap is real, and you should know it.

The Working Postmenopausal Target: 17 to 50 pg/mL

Longevity medicine practitioners, drawing on observational data from cohorts like the Women's Health Initiative and Nurses' Health Study, generally aim for a postmenopausal E1 in the range of approximately 17 to 50 pg/mL. The lower boundary is chosen because women with very low estrone (below about 10 to 15 pg/mL) show higher rates of bone loss. The relationship between low postmenopausal estrogens and fracture risk is quantified in a key analysis from the Study of Osteoporotic Fractures, which found that women in the lowest quartile of serum estrone had significantly higher rates of hip fracture than those in higher quartiles.

The upper boundary of 50 pg/mL is chosen with an eye to endometrial and breast tissue safety in women not on progesterone protection. Elevated endogenous postmenopausal estrogen levels have been associated with endometrial cancer risk in observational studies. This does not mean E1 above 50 pg/mL is automatically dangerous; it means the risk-benefit calculation shifts, and additional monitoring or progesterone co-administration becomes more relevant.

Why the E1:E2 Ratio Matters as Much as the Absolute Number

In women on hormone therapy who are using estradiol preparations (patches, gels, injections), measuring both E1 and E2 gives a more complete picture. A high E1:E2 ratio (for example, E1 substantially higher than E2) in a woman receiving estradiol can suggest excessive first-pass conversion, possibly from high adipose aromatase activity, or from an oral estrogen formulation that produces disproportionately high hepatic E1. Oral estradiol is metabolized to estrone in the gut wall and liver before reaching systemic circulation. The pharmacokinetic differences between oral and transdermal estradiol, including the higher E1 produced by the oral route, are described in a review in Menopause.

Transdermal and vaginal routes bypass first-pass metabolism and produce a more physiologic E2:E1 ratio. If longevity optimization of this ratio is a goal, the route of estrogen delivery matters.

Bone Health: The Floor Matters More Than the Ceiling

For skeletal protection, the evidence is clearest at the low end. A Framingham Heart Study analysis found that postmenopausal women with serum estrone above approximately 40 pg/mL had significantly better bone mineral density at the hip and spine compared to women below that threshold. This suggests that for bone health in particular, a floor of around 17 to 25 pg/mL is a reasonable target, with higher values not conferring additional skeletal risk.

Cognitive and Cardiovascular Considerations

The data on estrone specifically for cognitive outcomes is thinner than for estradiol. Most observational studies that report a potential neuroprotective benefit of postmenopausal estrogen used total estrogen or estradiol as the exposure variable, not estrone alone. You should know that extrapolating cognitive benefit from E1 levels specifically is at the limit of current evidence.

For cardiovascular outcomes, the picture is complicated by the timing hypothesis. The Kronos Early Estrogen Prevention Study (KEEPS) and the Danish Osteoporosis Prevention Study suggest that hormone therapy initiated near the time of menopause, within the "window of opportunity," carries different cardiovascular effects than therapy initiated years later. E1 levels in isolation do not resolve the timing question.

Conditions That Alter Estrone Levels in Women

PCOS (Polycystic Ovary Syndrome)

Women with PCOS frequently have elevated androstenedione, which aromatizes to estrone in peripheral tissues. This contributes to a persistently elevated E1 level even in reproductive-age women, creating a relatively unopposed estrogenic environment at the endometrium despite anovulation. The endocrine profile of PCOS including elevated androgen precursors and estrone is reviewed in a JCEM practice guideline. If you have PCOS, tracking E1 alongside androgens gives a more complete picture of your estrogen exposure than E2 alone.

Obesity and Metabolic Syndrome

Adipose tissue is a major extragonadal estrogen factory. In postmenopausal women, BMI is one of the strongest predictors of circulating E1. A woman with a BMI of 35 may have E1 levels two to three times higher than a lean counterpart of the same age. This is relevant for both breast and endometrial cancer risk discussions. The relationship between BMI and postmenopausal estrone is quantified in the Women's Health Initiative biomarker data.

Premature Ovarian Insufficiency

Women with premature ovarian insufficiency (POI), defined as loss of normal ovarian function before age 40, will typically have very low E1 levels alongside low E2 and elevated FSH. ACOG recommends hormone therapy for women with POI at least until the average age of natural menopause to address cardiovascular and skeletal risks. In this group, a longevity target for E1 is secondary to simply achieving physiologically adequate estrogen replacement.

Postpartum and Lactation

After delivery, estrogen levels fall sharply. Breastfeeding suppresses ovarian activity via elevated prolactin, keeping both E1 and E2 low during full lactation. This transient hypoestrogenic state is normal, does not require supplementation in healthy women, and is self-resolving when lactation wanes or stops. Testing E1 during breastfeeding is rarely clinically indicated.

Pregnancy and Lactation: What Happens to Estrone

During pregnancy, estrone rises steadily across all three trimesters, primarily as a result of fetoplacental unit production. By the third trimester, serum estrone reaches levels many times higher than any premenopausal cycle peak. Estriol (E3) becomes the dominant estrogen in late pregnancy, produced by the fetal adrenal glands and liver in conjunction with the placenta. The physiology of estrogen production in pregnancy, including the shift to estriol dominance, is covered in standard reproductive endocrinology texts and reviewed by ACOG.

Clinical bottom line for pregnancy: Estrone testing is not part of routine prenatal care. Estrone is not used to monitor pregnancy outcomes. The serum estrogen markers used in prenatal aneuploidy screening are different analytes measured in a different clinical context. Do not use a longevity-medicine E1 target range to interpret a result obtained during pregnancy.

Lactation: As noted above, E1 remains low during full breastfeeding. Vaginal dryness and reduced libido during this period reflect the low-estrogen state driven by prolactin suppression of the hypothalamic-pituitary-ovarian axis, not a pathological deficiency requiring treatment in most women. Low-dose vaginal estrogen, if needed for severe genitourinary symptoms, transfers minimally into breast milk and is considered acceptable by the Academy of Breastfeeding Medicine in limited circumstances; systemic estrogen therapy to raise E1 is generally avoided during lactation.

Who Should Order an Estrone Test?

Estrone testing is not part of standard annual bloodwork and is not ordered for most women. Targeted indications include:

• Postmenopausal women on hormone therapy where the route of delivery (especially oral estrogen) or dose adjustment needs monitoring
• Women with POI on hormone replacement who need confirmation of adequate estrogen exposure
• Postmenopausal women with unexplained vaginal bleeding where endogenous hyperestrogenism from adipose aromatization is suspected
• Women with PCOS where a complete picture of the estrogen environment is needed beyond E2 alone
• Women engaged in formal longevity medicine programs where a full hormone panel, including E1, is part of a periodic biomarker assessment

Estrone alone answers almost nothing. It is interpreted alongside E2, FSH, SHBG, clinical symptoms, bone density data, and relevant cancer screening.

Life-Stage Summary Table

| Life Stage | Typical E1 Range (LC-MS/MS) | Clinical Priority | |---|---|---| | Follicular phase (reproductive) | 37 to 138 pg/mL | Low; E2 is the relevant marker | | Perimenopause | Variable; overlaps both ranges | FSH and symptoms more useful | | Early postmenopause (no HRT) | 7 to 40 pg/mL | Relevant for bone and HRT monitoring | | Postmenopause on oral estrogen | Often 60 to 200+ pg/mL | E1:E2 ratio guides route decisions | | Postmenopause on transdermal E2 | Closer to physiologic E1:E2 | Monitor per longevity target 17 to 50 pg/mL | | POI | Very low, similar to postmenopause | Replacement adequacy check | | Pregnancy | Markedly elevated, trimester-dependent | Not clinically indicated to test | | Lactation | Low, suppressed | Not clinically indicated to test |

How Estrone Is Measured and Why Assay Type Changes Everything

Your estrone result means almost nothing without knowing which assay your lab used. Standard hospital immunoassays overestimate estrogen at low postmenopausal concentrations by a factor of two or more. The overestimation of low-level estrogens by immunoassay compared to LC-MS/MS is documented in a 2013 JCEM paper. If your longevity-medicine practitioner is using a target of 17 to 50 pg/mL, that target is calibrated to LC-MS/MS values. Plugging an immunoassay result into that range will give you a misleading picture.

Ask your clinician which platform your specimen was processed on. Major reference laboratories including Quest Diagnostics and LabCorp offer LC-MS/MS estrone panels, but standard physician-ordered "estrogen" tests often default to immunoassay unless specified otherwise.

Interpreting Your Result: A Practical Framework

When you receive your estrone result, run through these four questions:

1. What assay was used? LC-MS/MS values are comparable to longevity targets. Immunoassay values are not directly comparable without knowing the conversion factor for your lab.

2. What is your life stage? A postmenopausal E1 of 35 pg/mL is reassuring. The same result in a 32-year-old in the follicular phase is at the low end of normal and may reflect cycle timing or assay variability.

3. Are you on hormone therapy, and by what route? Oral estrogen predictably produces a high E1 relative to E2. If your E1 is 180 pg/mL and you are on oral estradiol, that is an expected pharmacokinetic result, not a disease state. Switching to transdermal delivery will lower E1 and raise E2.

4. What are your symptoms and bone data? A postmenopausal woman with E1 of 12 pg/mL, worsening hot flashes, and declining bone density at DEXA has a different clinical picture than a woman with E1 of 12 pg/mL who is asymptomatic with stable bone density. The number serves the clinical picture; it does not replace it.

Estrogen Fractions and Cancer Risk: What the Data Actually Say

Elevated endogenous postmenopausal estrone, driven by adiposity, is associated with higher breast cancer risk in observational studies. A large meta-analysis in the Journal of the National Cancer Institute found that postmenopausal women in the highest quartile of serum estrone had approximately twice the breast cancer risk of women in the lowest quartile. This is an association in observational data, not a proven causal chain, and it reflects endogenous E1 driven by adiposity, not estrogen therapy at physiologic replacement doses.

For endometrial cancer, the risk from elevated E1 is more mechanistically direct. Unopposed estrogen (E1 or E2) stimulates endometrial proliferation. In postmenopausal women with a uterus, any estrogen therapy must be paired with adequate progestogen. The Menopause Society position statement on hormone therapy affirms that progestogen is required for endometrial protection in women with a uterus. Endogenous E1 elevation from adipose aromatization does not carry the same legal or prescribing obligation, but it does warrant endometrial surveillance if unexplained postmenopausal bleeding occurs.

Estrone and the Evidence Gap: What We Do Not Yet Know

Women have been underrepresented in hormone-biology research for decades, and estrone specifically has received far less attention than estradiol in clinical trials. Most trials that informed hormone therapy guidelines measured E2, not E1, as the relevant biomarker. The longevity target range of 17 to 50 pg/mL for postmenopausal E1 is not derived from a randomized trial that assigned women to specific E1 bands and measured 10-year outcomes. It is an extrapolation from observational data and clinical reasoning.

What we know with reasonable confidence:

• Very low postmenopausal E1 (below about 10 to 15 pg/mL) is associated with worse bone outcomes. The Study of Osteoporotic Fractures confirmed this association.
• Very high endogenous postmenopausal E1 (driven by obesity) is associated with higher breast and endometrial cancer risk in observational data.
• The optimal middle range for longevity is inferred, not proven by trial.

What we do not know:

• Whether targeting a specific E1 range with exogenous hormones produces better long-term outcomes than targeting E2 alone
• Whether the E1:E2 ratio is a useful clinical target in its own right or mainly a marker of delivery route
• How E1 targets should be adjusted for women with genetic variants in estrogen metabolism genes (CYP1B1, COMT, and others)

Honest acknowledgment of these gaps is not a reason to dismiss E1 testing. It is a reason to interpret it within a full clinical context rather than chase a number in isolation.